Brief: Xspray Pharma Receives Request For Additional Information Concerning Dasynoc From FDA
11/07/2023 08:22
July 11 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST :
* XSPRAY PHARMA RECEIVES REQUEST FOR ADDITIONAL INFORMATION
CONCERNING DASYNOC FROM FDA
* FDA REQUEST ADDITIONAL INFORMATION REGARDING ADDITIONAL
INFORMATION TO DOCTORS, USERS RELATED TO DASYNOC DOSINGA,
THIRD-PARTY MANUFACTURING FACILITY
Source text for Eikon: ID:nMFN58HQ2W
Further company coverage: XSPRAY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003